Floatz Rating
B60/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02453620CT.gov Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02115282CT.gov Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Entinostat (this asset) | National Cancer Institute (NCI) | P3 | B · 60 |
| Cyclophosphamide | Second Affiliated Hospital, School of Medicine, Zhejiang University | P3 | BB |
| Trastuzumab | Academic and Community Cancer Research United | P3 | BB |
| Letrozole | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P4 | BB |
| Adriamycin | Virginia Commonwealth University | P3 | BB |
| Carboplatin | Genmab | P3 | BB |
| Pembrolizumab | Genmab | P2 | BB |
| Pertuzumab | Academic and Community Cancer Research United | P3 | BB |
| Eribulin Monomethanesulfonate | Montefiore Medical Center | P3 | BB |
+42 more in the Breast Adenocarcinoma cohort
Other indications for Entinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Triple-Negative Breast Carcinoma | — | P2 | B · 63 |
| Myelodysplastic Syndrome | — | P2 | B · 62 |
| Breast Carcinoma | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Entinostat in Breast Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/entinostat-breast-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →